Xilio Therapeutics Announces Preclinical Data Demonstrating Anti-Tumor Activity and Tolerability of XTX301, a Tumor-Selective IL-12, at Society for Immunotherapy in Cancer Annual Meeting

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition